Douglas M. Schirle
Analyst · Anthology Capital
Thank you, Lee Lean. For the quarter ended June 30, 2013, we reported a net loss of $441,000 or $0.02 per diluted share on net revenues of $16.4 million compared to net income of $920,000 or $0.03 per diluted share on net revenues of $16.8 million in the quarter ended June 30, 2012. In the prior quarter ended March 31, 2013, we reported net income of $950,000 or $0.03 per diluted share on net revenues of $15.7 million. First quarter direct and indirect sales to Cisco Systems were $2.8 million or 17.1% of net revenues compared to $3.9 million or 24.8% of net revenues in the prior quarter and $4.1 million or 24.2% of net revenues in the same period a year ago. Military/defense sales were 13.3% of shipments compared to 12.7% of shipments in the prior quarter and 11.9% of shipments in the comparable period a year ago. SigmaQuad sales were 41.6% of shipments compared to 38.9% in the prior quarter and 38% in the first quarter of fiscal 2013. First quarter fiscal 2014 operating loss was $541,000 compared to operating income of $439,000 or 2.8% of net revenues in the prior quarter and $880,000 or 5.2% of net revenue a year ago. Total operating expenses in the first quarter of 2014 were $8 million, up from $6.8 million in the prior quarter and up from $5.9 million in the first quarter of fiscal 2013. Research and development expense was $3 million compared to $2.9 million in the prior quarter and $2.8 million in the year ago quarter. But selling, general and administrative expense of $5 million, which includes litigation-related expenses, was up substantially from $3.9 million in the current quarter and $3 million in the fiscal quarter ended June 30, 2012. Included in SG&A during these periods were, respectively, $2.3 million, $1.2 million and $455,000 in litigation-related expenses. Total first quarter pre-tax stock-based compensation expense was $565,000 compared to $589,000 in the prior quarter and $562,000 in the comparable quarter a year ago. At June 30, 2013, the company has $63.8 million in cash, cash equivalents and short-term investments, $41.4 million in long-term investments, $82 million in working capital, no debt, and stockholders' equity of $133.2 million. Accounts payables at June 30, 2013 was $3.5 million compared to $3.8 million at March 31. Net inventory was $12.2 million at June 30, 2013, down from $13.8 million at March 31, 2013. Inventory turns at June 30, 2013 were 2.9x compared to 2.4 at March 31, 2013. Depreciation and amortization expense was $494,000 for the quarter. We currently expect net revenues in the second quarter of fiscal 2014 to be in the range of $16 million to $17 million, with gross margin of approximately 45%. We also expect that ongoing legal expenses related to the patent litigation and antitrust litigation will continue to affect operating income and our bottom line. These expenses are difficult to forecast, but we currently estimate that they will be approximately $1.6 million in the second quarter. Operating expenses in total are expected to be approximately $8 million and will include approximately $850,000 for an R&D mass set for 288 MB device, which will be our first 40-nanometer tape-out, in addition to the estimated litigation expenses, $1.6 million. Operator, at this point, we'll open the call to Q&A.